Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Launched by PFIZER · Aug 24, 2010
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
The study population will be described using standard descriptive statistics for demographic, clinical, medical, characteristics, as well as for standard health-related quality of life and functional disability questionnaires .
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Proven diagnosis of Ankylosing Spondylitisin accordance with local guidelines
- • Patients treated as an outpatient
- Exclusion Criteria:
- • Patients who suffer from hypersensitivity to the active substance Etanercept or to any of the excipients of Enbrel®.
- • Treatment with Enbrel® should not be initiated in patients with active infections including chronic or localised infections.
- • Patients with sepsis or risk of sepsis should not be treated.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials